Senti Bio announces 37% headcount reduction

Senti Biosciences announced plans to streamline its business operations, including reducing its workforce by approximately 37% to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia. The Investigational New Drug application for SENTI-202 was cleared by the U.S. FDA in December 2023 and the company anticipates dosing the first patient in the second quarter of 2024. Additionally, the company will continue to support the clinical development activities of SENTI-301A for the treatment of advanced glypican 3-expressing hepatocellular carcinoma in China through its partnership with Celest Therapeutics. The company expects that these resource allocation efforts, combined with other expected receivables, will extend its cash runway into the first quarter of 2025.